Market closedNon-fractional

Mersana Therapeutics/MRSN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Mersana Therapeutics

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Ticker

MRSN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

123

MRSN Metrics

BasicAdvanced
$224M
Market cap
-
P/E ratio
-$1.13
EPS
1.49
Beta
-
Dividend rate
$224M
1.49
3.512
3.429
89.191
120.475
-26.43%
-33.91%
-292.19%
5.714
8.03
8.03
-1.258
18.40%
-46.66%
258.96%
-10.66%

What the Analysts think about MRSN

Analyst Ratings

Majority rating from 9 analysts.
Buy

MRSN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-209.78% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$9.2M
-14.02%
Net income
-$19M
-1.03%
Profit margin
-209.78%
15.11%

MRSN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.60%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.35
-$0.16
-$0.16
-
Expected
-$0.44
-$0.36
-$0.16
-$0.18
-$0.17
Surprise
6.47%
-3.29%
-2.64%
-11.60%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Mersana Therapeutics stock?

Mersana Therapeutics (MRSN) has a market cap of $224M as of July 06, 2024.

What is the P/E ratio for Mersana Therapeutics stock?

The price to earnings (P/E) ratio for Mersana Therapeutics (MRSN) stock is 0 as of July 06, 2024.

Does Mersana Therapeutics stock pay dividends?

No, Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Mersana Therapeutics dividend payment date?

Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders.

What is the beta indicator for Mersana Therapeutics?

Mersana Therapeutics (MRSN) has a beta rating of 1.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Mersana Therapeutics stock

Buy or sell Mersana Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing